Yuanjin Zhang

Changning Maternity And Infant Health Hospital And Shanghai Key Laboratory Of Regulatory Biology
Changning, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Mechanistic insights into cytochrome P450 inhibition by progesterone and its impact on fluoxetine pharmacokinetics.

Mechanistic insights into cytochrome P450 inhibition by progesterone and its impact on fluoxetine pharmacokinetics.

Journal: Biochemical pharmacology

Published: June 25, 2026

Development of an LC-MS/MS method to quantitatively analyze escitalopram and its metabolites with application in liver and placenta microsome metabolism.

Development of an LC-MS/MS method to quantitatively analyze escitalopram and its metabolites with application in liver and placenta microsome metabolism.

Journal: Frontiers in pharmacology

Published: September 28, 2025

Metabolism of nifedipine by placental CYP19A1 and competitive inhibition by chlorpromazine.

Metabolism of nifedipine by placental CYP19A1 and competitive inhibition by chlorpromazine.

Journal: Biochemical pharmacology

Published: August 26, 2025

CYP3A mediates drug-drug interactions between atorvastatin and omeprazole: Evidence from in vitro and in vivo studies.

CYP3A mediates drug-drug interactions between atorvastatin and omeprazole: Evidence from in vitro and in vivo studies.

Journal: Biochemical pharmacology

Published: June 15, 2025

Carboxylesterase 2A gene knockout or enzyme inhibition alleviates steatohepatitis in rats by regulating PPARγ and endoplasmic reticulum stress.

Carboxylesterase 2A gene knockout or enzyme inhibition alleviates steatohepatitis in rats by regulating PPARγ and endoplasmic reticulum stress.

Journal: Free radical biology & medicine

Published: January 14, 2025

Non-alcoholic fatty liver disease changes the expression and activity of hepatic drug-metabolizing enzymes and transporters in rats.

Non-alcoholic fatty liver disease changes the expression and activity of hepatic drug-metabolizing enzymes and transporters in rats.

Journal: Toxicology letters

Published: March 13, 2024

Construction of cytochrome P450 3A and P-glycoprotein knockout rats with application in rivaroxaban-verapamil interactions.

Construction of cytochrome P450 3A and P-glycoprotein knockout rats with application in rivaroxaban-verapamil interactions.

Journal: Biochemical pharmacology

Published: February 27, 2024

Construction and characterization of a humanized SLCO1B1 rat model with its application in evaluating the uptake of different statins.

Construction and characterization of a humanized SLCO1B1 rat model with its application in evaluating the uptake of different statins.

Journal: Acta pharmaceutica Sinica. B

Published: September 21, 2023

Establishment of LC-MS/MS method for quantifying chlorpromazine metabolites with application to its metabolism in liver and placenta microsomes.

Establishment of LC-MS/MS method for quantifying chlorpromazine metabolites with application to its metabolism in liver and placenta microsomes.

Journal: Journal of pharmaceutical and biomedical analysis

Published: March 17, 2023

Design and Construction of Carboxylesterase 2c Gene Knockout Rats by CRISPR/Cas9.

Design and Construction of Carboxylesterase 2c Gene Knockout Rats by CRISPR/Cas9.

Journal: Current drug metabolism

Published: September 11, 2022

Emerging role of carboxylesterases in nonalcoholic fatty liver disease.

Emerging role of carboxylesterases in nonalcoholic fatty liver disease.

Journal: Biochemical pharmacology

Published: June 28, 2022

Investigation of cytochrome P450 inhibitory properties of deoxyshikonin, a bioactive compound from Lithospermum erythrorhizon Sieb. et Zucc.

Investigation of cytochrome P450 inhibitory properties of deoxyshikonin, a bioactive compound from Lithospermum erythrorhizon Sieb. et Zucc.

Journal: Phytotherapy research : PTR

Published: March 25, 2022

Showing 1-12 of 28

Last Updated: 09/26/2026